|会社名||Regeneron Pharmaceuticals Inc. （リジェネロン・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 リジェネロン・ファーマシューティカルズ(Regeneron Pharmaceuticals Inc)は重症疾患に使われる医薬品の発見・発明・開発・生産・商品化を行うバイオ医薬品会社である。同社は眼疾患、高密度リポタンパク質（LDL）コレステロール、炎症性疾患の医薬品を商品化し、慢性関節リウマチ、喘息、アトピー性皮膚炎、疼痛、がん、感染症などの分野に開発する製品候補を有する。同社は、EYLEA（aflibercept）注射剤、Praluent（アリロクマブ）注射剤、ARCALYST（rilonacept）皮下注射剤、Kevzara（sarilumab）皮下注射剤、ZALTRAP（ziv-aflibercept）注射剤を販売する。 リジェネロン・ファ―マシュ―ティカルズは米国の大手バイオ医薬品会社。主にがん、眼病、炎症に対する治療薬の開発、製造、販売に従事。主要な製品は加齢黄斑変性症と網膜中心静脈閉塞の黄斑浮腫治療薬「EYLEA」、転移性結腸直腸がん治療薬「ZALTRAP」、抗炎症剤「ARCALYST」など。本社はニューヨーク州。 Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.|
|本社所在地||777 Old Saw Mill River Road Tarrytown NY 10591-6707 USA|
|代表者氏名||P. Roy Vagelos P. Roy Vagelos|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Regeneron Pharmaceuticals Inc revenues increased 12% to $3.12B. Net income increased 62% to $1.03B. Revenues reflect Net product sales increase of 11% to $1.98B Bayer Collaboration Revenue increase of 26% to $510.8M Other revenue increase of 16% to $197.2M. Net income benefited from Payroll and Benefits decrease of 4% to $280.7M (expense).|
Markel Gayner Asset Management Corp Buys Regeneron Pharmaceuticals Inc, Texas Pacific Land ... 2021/08/06 22:38:01 GuruFocus
Related Stocks: REGN , EMN , CE , LMT , TWTR , IAC , TPL , MRVL , MTSI , BAMR , CRM , ROP , EA ,
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients 2021/08/05 18:43:34 Benzinga
Exicure Inc (NASDAQ: XCUR ) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid tumors refractory to anti-PD-(L)1 therapy. The trial is assessing cavrotolimod in combination with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) or Sanofi SA (NASDAQ: SNY ) - Regeneron Pharmaceuticals Inc''s ( NASDAQ: REGN) Libtayo (cemiplimab) in two primary dose-expansion cohorts, one in Merkel cell carcinoma (MCC) Full story available on Benzinga.com
Regeneron Pharmaceuticals Inc. (REGN) CEO Leonard Schleifer on Q2 2021 Results - Earnings Call Transcript 2021/08/05 18:32:12 Seeking Alpha
Regeneron Pharmaceuticals Inc (REGN) EVP Commercial Marion Mccourt Sold $577,120 of Shares 2021/08/05 18:15:08 GuruFocus
Related Stocks: REGN ,
Regeneron Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation 2021/08/05 16:24:51 Seeking Alpha
Hasil Penelitian: Terapi Regeneron Kurangi Keparahan Akibat Covid-19 2021/06/22 01:00:36 Solopos
Solopos.com, SOLO--Berdasarkan sebuah penelitian di Inggris, terapi regenoren disebut-sebut dapat membangun antibodi terhadap coronavirus. Terapi tersebut dikembangkan oleh Regeneron Pharmaceuticals dan Roche. Lantas seperti apa terapi regeneron? Benarkah ampuh mengurangi komplikasi Covid-19? Simak ulasannya di info sehat kali ini. Menurut dokter dari Klikdokter.com, Atika, terapi regeneron bekerja menggunakan antibodi monoklonal atau antibodi buatan. Terapi ini  The post Hasil Penelitian: Terapi Regeneron Kurangi Keparahan Akibat Covid-19 appeared first on Solopos.com .
An inside look at Regeneron as Covid exploded 2021/06/21 10:48:32 westfaironline
While the Covid-19 virus was knocking the world off balance, scientists, production experts, office managers, logistics personnel and others at Regeneron Pharmaceuticals Inc. were gearing up in a monumental effort to find a therapy that could save lives. Regeneron had the financial as well as human resources needed for such an effort, having reported more  The post An inside look at Regeneron as Covid exploded appeared first on Westfair Communications .
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day 2021/06/19 01:44:46 MarketWatch
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day MarketWatch
Thuc kháng th giúp gim nguy c t vong do Covid-19 2021/06/18 01:29:45 VnExpress
Mt loi thuc kháng th ca hãng Regeneron Pharmaceuticals c chng minh giúp gim áng k nguy c t vong mt s bnh nhân Covid-19 nhp vin.
Pfizer treatment cuts severe Covid-19 deaths by 40% in trial 2021/06/17 12:50:00 Proactive Investors UK
A second study this week has demonstrated a new Covid-19 treatment that can reduce deaths in patients suffering from the most severe symptoms of the virus. Pfizer Inc (NYSE:PFE) said almost 40% fewer patients (18%) treated with Xeljanz, an oral rheumatoid arthritis drug, died in the study compared with those given a placebo (29%). The study was carried out over 28 days in a hospital in Sao Paolo, Brazil on people suffering severe respiratory failure due to Covid-19. Xeljanz or tofacitinib is a new kind of drug known as a JAK inhibitor, that is being used to boost immune responses in patients suffering from rheumatoid arthritis. As yet, tofacitinib has not been approved to treat Covid-19 in any country and comes with a number of warnings about potential side effects. We are encouraged by the initial findings of our randomized trial of tofacitinib in patients hospitalized with COVID-19 pneumonia," said Otavio Berwanger, Director of the Academic Research Organization, Hospital Israelita Albert Einstein. "These results provide new information which indicates that the use of tofacitinib when added to standard of care, which includes glucocorticoids, may further reduce the risk of death or respiratory failure in this patient population, Tamas Koncz, Chief Medical Officer, Pfizer Inflammation & Immunology. added: To effectively combat the COVID-19 pandemic, there remains a critical need for multiple therapeutic options to treat patients who have contracted the virus, said Earlier this week, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said its antibody cocktail cuts the risk of death when given to patients hospitalised with severe COVID-19 that havent built an immune response to the virus.
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics 2021/06/03 12:00:42 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Fortress Biotech (NASDAQ: FBIO ) creates partner companies to manage and optimize cancer immunotherapy and other disease treatment development programs. Its broad portfolio of therapeutic categories includes oncology, rare disorders, gene therapy, neurology, pain management, dermatology and infectious disease. Fortress believes its unique and progressive structure builds in enhanced financial leverage and flexibility, with the ability to monetize assets more fluidly. With more than 25 pipeline programs, Fortress’ reach has expanded into 11 partner companies. Three have gone public: Checkpoint Therapeutics (NASDAQ: CKPT ), Mustang Bio (NASDAQ: MBIO ) and Avenue Therapeutics (NASDAQ: ATXI ), in which Fortress Biotech retains approximately 18% to 23% ownership stakes.
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Annual Bernstein Strategic Decisions Conference (Transcript) 2021/06/02 18:33:03 Seeking Alpha
U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment 2021/05/28 14:44:41 MarketWatch
The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday. Coronavirus cases associated with these variants now make up more than 10% of all cases in Arizona, California, Florida, Illinois, Indiana, Massachussetts, Oregon, and Washington. Instead, the agency recommends using Regeneron Pharmaceuticals Inc.'s antibody treatment. This is not the first time there has been concern about bamlanivimab's effectiveness. The Food and Drug Administration in April pulled the emergency authorization for bamlanivimab as a standalone treatment over concerns about its effectiveness against variants. There are three authorized antibody cocktails in the U.S., developed by Lilly, Regeneron, and Vir Biotechnology Inc. /GlaxoSmithKline .
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 リジェネロン・ファ―マシュ―ティカルズ REGN Regeneron Pharmaceuticals Inc.）